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Changes in the use of anti-asthmatic
medication in an international cohort
C. Janson*, R. de Marco#, S. Accordini#, E. Almar", M. Bugiani+, A. Carolei1,
L. Cazzoletti#, I. Cerverie, A. Corsicoe, E. Duran-Tauleria**, D. Gislason##,
A. Gulsvik"", R. Jo˜gi++, A. Marinoni1, J. Martı´nez-Moratalla11, I. Pinee,
P. Vermeire*** and D. Jarvis###
ABSTRACT: The aim of this study was to describe changes in pharmacotherapy for asthma since
the early 1990s in an international cohort of young and middle-aged adults.
A total of 28 centres from 14 countries participated in a longitudinal study. The study included
8,829 subjects with a mean follow-up time of 8.7 yrs. Change in the prevalence of use for
medication was expressed as absolute net change (95% confidence interval) standardised to a 10-
yr period.
The use of anti-asthmatics was found to have increased by 3.1% (2.4–3.7%) and the prevalence
of symptomatic asthma by 4.0% (3.5–4.5%). In the sample with asthma in both surveys (n5423),
the use of inhaled corticosteroids increased by 12.2% (6.6–17.8%). Despite this, only 17.2% were
using inhaled corticosteroids on a daily basis at follow-up. Females with continuous asthma were
more likely, compared with males, and smokers with asthma, to have started using inhaled
corticosteroids since the first survey.
The use of anti-asthmatics has increased in a pattern consistent with current consensus on
treatment. However, despite increased use of inhaled corticosteroids, a large majority of subjects
with symptomatic asthma do not use this treatment on a daily basis, particularly males and
smokers with asthma.
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A
common theme in asthma management
guidelines published in the 1990s [1–4] is
to emphasise the use of inhaled cortico-
steroids (ICS) as the first line of treatment in
persistent asthma. Drug sales, expressed as a
daily defined dose per 1,000 inhabitants, show an
increase in ICS in many countries [5–7], though
it is not known to what extent regular use
of ICS has actually increased in asthmatics. The
European Community Respiratory Health Survey
I (ECRHS I) was conducted between 1990 and
1994. In accordance with other studies [8–11], the
current study found large differences in the
treatment of asthma in different countries [12].
The European Community Respiratory Health
Survey II (ECRHS II), a follow-up study of the
subjects that were investigated in the ECRHS I,
provides a unique opportunity to study changes
in the treatment of asthma as reported by people
with asthma in populations from a large number
of different countries.
The aim of this investigation was to study how
anti-asthmatic pharmacotherapy and particularly
ICS have changed after the introduction of the
Global Initiative for Asthma (GINA) guidelines
in an international cohort of young and middle-
aged adults. A secondary aim was to identify
factors that were related to the use of ICS in
individual participants.
METHODS
The design of ECRHS I and ECRHS II have been
published in detail (fig. 1) [13, 14]. Each partici-
pant was sent a brief questionnaire (stage 1) and
from those who responded, a random sample
was selected to undergo a more detailed clinical
examination (stage 2). In addition a ‘‘sympto-
matic sample’’, reporting symptoms of waking
with shortness of breath, asthma attacks or using
asthma medication in stage 1 were also studied.
In ECRHS II, subjects who had participated in
stage 2 of ECRHS I, were invited to participate in
the follow-up. Four centres (in Germany, the
Netherlands and the USA) were not able to
follow-up the whole of the eligible sample and
selected a representative subsample. This analy-
sis includes data from 28 centres in ECRHS
II (table 1). The target population was 14,530
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subjects from the random population that had answered
questions on asthma medication in stage 2 of ECRHS I. Of
these, 8,829 (60.8%) supplied data on the use of medication in
ECRHS II. In addition, 2,463 subjects from the symptomatic
sample had participated in ECRHS I. Of these, 1,652 (67.1%)
took part in ECRHS II (fig. 1).
Questionnaire and definitions
The subjects underwent a structured interview, which
included detailed information on respiratory symptoms,
asthma and asthma therapy. Pictures, samples or lists of
different anti-asthmatic medications were shown to facilitate a
correct answer to the therapy questions. Local ethics commit-
tees at each centre approved the study protocols.
Definition of asthma-related variables
Physician-diagnosed asthma was defined as a positive answer
to the questions ‘‘Have you ever had asthma?’’ and ‘‘Was this
confirmed by a doctor?’’
Asthma-related symptoms were classified as wheeze, noctur-
nal chest tightness, attacks of breathlessness following activity,
at rest or at night time during the previous 12 months.
Symptomatic asthma was defined physician-diagnosed asthma
and asthma-related symptoms or attacks of asthma in the
previous 12 months.
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FIGURE 1. Study population in the different stages of the European
Community Respiratory Health Surveys (ECRHS) I and II.
TABLE 1 Prevalence of asthma treatment use and change between the European Community Respiratory Health Surveys
(ECRHS) I and II
Country Centre Subjects n Response % ECRHS I % ECRHS II % Follow-up yrs Net change?10 yrs-1
Iceland Reykjavik 458 81.8 3.9 7.2 8.9¡0.3 3.6 (1.8–6.2)
Norway Bergen 595 70.3 3.6 7.7 9.5¡0.2 4.3 (2.0–6.6)
Sweden Go¨teborg 484 70.7 7.0 11.4 9.1¡0.4 4.8 (2.1–7.4)
Umea˚ 421 76.4 8.3 11.4 8.5¡0.4 3.5 (0.0–7.0)
Uppsala 510 82.3 6.5 11.6 8.6¡0.4 5.8 (3.2–6.5)
Estonia Tartu 241 55.9 2.5 4.6 7.0¡0.5 2.9 (0.3–5.4)
Germany Hamburg 303 33.7 5.0 9.2 9.3¡0.6 4.6 (1.6–7.6)
Erfurt 286 40.0 2.8 7.3 9.2¡0.3 4.9 (1.9–7.9)
The Netherlands Geleen 138 37.3 2.2 9.4 10.3¡0.3 7.0 (2.4–11.6)
Belgium Antwerp South 338 60.7 4.4 8.0 9.8¡0.4 3.6 (0.3–6.9)
Antwerp City 297 52.7 4.7 8.1 9.2¡0.4 3.6 (0.3–7.0)
Switzerland Basel 457 53.7 3.3 6.6 10.3¡0.4 3.2 (1.6–4.7)
France Bordeaux 157 28.9 12.7 17.2 9.2¡0.5 5.0 (0.1–9.8)
Grenoble 302 63.8 9.3 11.9 9.0¡0.4 2.9 (-0.3–6.1)
Montpellier 199 43.6 10.0 9.6 9.2¡0.7 -0.2 (-4.4–3.9)
Paris 431 66.3 7.9 10.2 8.2¡0.9 2.8 (0.0–5.6)
UK Ipswich 287 68.5 11.5 15.3 8.5¡0.5 4.3 (0.4–11.6)
Norwich 257 54.1 10.9 12.1 9.0¡0.5 1.3 (-2.6–5.2)
Italy Pavia 191 61.8 7.8 3.7 8.5¡0.7 -5.2 (-9.2– -1.1)
Turin 123 50.4 8.9 8.1 8.4¡0.4 -0.9 (-5.9–4.0)
Verona 205 59.6 6.9 6.9 8.7¡0.6 0.4 (-3.7–4.5)
Spain Barcelona 265 67.8 3.4 7.2 8.9¡0.6 4.1 (0.6–7.6)
Galdakao 359 73.9 1.4 3.9 8.6¡0.4 3.0 (0.9–5.0)
Albacete 307 70.6 5.5 8.5 8.7¡0.8 3.3 (-0.6–7.2)
Oveido 240 67.6 5.8 7.5 8.4¡0.7 1.8 (-2.0–5.8)
Huevla 204 75.3 6.4 6.9 8.4¡0.7 0.5 (-3.9–4.8)
USA Portland 197 51.8 12.2 11.2 7.7¡0.4 -1.6 (-8.2–4.5)
Australia Melbourne 483 72.2 18.0 18.6 5.1¡0.4 1.0 (-5.1–7.1)
All subjects 8829 60.8 6.8 9.5 8.7¡1.2 3.1 (2.4–3.7)
Data presented as mean¡SD or % (95% confidence interval), unless otherwise stated.
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New asthma was categorised as symptomatic asthma in
ECRHS II but not in ECRHS I.
Continuous asthma was defined as diagnosed symptomatic
asthma in both surveys.
Anti-asthmatic medication was categorised as reportedly
taking any of the following drugs in the previous 12 months.
1) Inhaled anti-asthmatics: short-acting b2-agonist, long-acting
b2-agonists, anticholinergic agents, ICS and cromones. Patients
who used inhalers with the combination of ICS and long-acting
b2-agonists were coded as using both kinds of drugs. 2) Oral
anti-asthmatic medication: b2-agonist, theophylline, ketotifen,
antileukotrienes and oral corticosteroids. In addition, daily use
of the following drugs was analysed: short-acting b2-agonists,
long-acting b2-agonists and ICS.
Inhaled corticosteroids doses were divided into the following
categories: low dose ,500 mg, medium dose 500–1,000 mg, high
dose .1,000 mg, daily in doses equivalent to beclomethasone
[15].
Hospitalisation was defined as reporting to have spent at least
one night at hospital because of breathing problems within the
previous 12 months
Doctor visits were defined as having seen a doctor because of
breathing problems within the previous 12 months.
Socio-economic status was defined using information on the
subject’s occupation provided during ECRHS I, according
to the UK social classification [16]. Using this classification
the subjects were divided into: 1) professional and semi-
professionals, 2) skilled non-manual workers, 3) manual
workers and 4) undefined. A low educational level was
defined as having completed full time education before the
age of 16 yrs [17].
Based on the information on smoking in both surveys the
subjects were classified into: never-smoker, ex-smoker (before
ECRHS I), quitter (between ECRHS I and II), starter (between
ECRHS I and II) and persistent smoker. Since the number of
subjects that started smoking between the surveys was low
(n5256) the starters and persistent smokers were merged
together to form one category called smoker.
Statistics
Analysis was carried out using Stata 8.0. Absolute net change in
treatment status per year of follow-up was estimated using
population averaged, generalised estimating equations for a
binomial outcome with identity link, with participants identi-
fied as the clustering factor and length of follow-up as an
independent variable. Results were expressed as net change per
10 yrs of follow-up. The Wald test was used to examine
differences in change of prevalence by age group and sex. To
study the determinants of the use of ICS during the follow-up,
the analysis was restricted to continuous asthmatics that
were not using ICS in ECRHS I. A logistic regression model
was fitted to the data using, as outcome, a dummy variable
contrasting subjects that started to use ICS during the
follow-up against never-users. Estimates by centre (random
populations) or country (continuous asthmatics) were examined
for heterogeneity and combined using random effect meta-
analysis. The randomly selected population was used in all
analyses except when analysing determinants of the use of ICS
where the random and symptomatic samples were combined.
RESULTS
The analyses of the random population samples included 4,215
males and 4,614 females that participated both in ECRHS I and
II. The mean¡SD ages of the participants in the two surveys
were 34.0¡7.1, (range 20–48) and 42.8¡7.1, (range 26–57) yrs
respectively.
Participants and non-participants
The non-participants in ECRHS II were slightly younger
(32.9¡7.2 versus 33.9¡7.1 yrs) and more likely to be smokers
in ECRHS I (43.0 versus 35.2%) than subjects that participated
in both ECRHS I and II. There were no significant differences
in sex distribution, social classification, prevalence of asthma
or the use of medication between those who participated in
the follow-up and those who did not. Asthmatics in ECRHS
I that did not participate in the follow-up were slightly
younger (31.9¡7.2 versus 33.8¡7.0 yrs) and more often
smokers (39.6 versus 27.9%) than asthmatics that participated
in the follow-up.
Change in anti-asthmatic treatment in the general
population
The overall use of anti-asthmatic medication increased
significantly (table 1). When analysing individual centres, an
increased prevalence of treatment was found in most.
Significant between-centre heterogeneity was found (p50.04),
but this heterogeneity was explained by a significantly reduced
prevalence of medication in one centre (Pavia, Italy) and
exclusion of this centre from the analysis showed no hetero-
geneity (p50.58). Similar increases were observed in both sexes
at all ages.
Therapy of asthma in different countries
In the random sample of ECRHS I, 894 subjects had
symptomatic asthma and 494 of these subjects were reinves-
tigated in ECRHS II (fig. 2). The overall prevalences of
symptomatic asthma in subjects from the random sample of
ECRHS I who were investigated both in the ECRHS I and II,
were 5.5 and 9% respectively. The absolute net change was 4.0
(3.5, 4.5)%?10 yrs-1. Of the 794 subjects that had symptomatic
asthma in ECRHS II, 370 (45.9%) had new asthma and 424 had
asthma in both surveys (fig. 2). Of the subjects with new
asthma, 51 had a diagnosis of asthma but no symptoms in
ECRHS I, whilst 319 had been diagnosed as having asthma
between the two surveys. The prevalence of use of short-acting
b2-agonists and oral anti-asthmatics was higher in the group of
subjects with continuous asthma than in those with new
asthma (57.2 versus 44.6%, p50.0001 and 11.1 versus 6.6%,
p50.03, respectively), whereas there was no significant
difference in the use of ICS. The prevalence of ICS used daily
was 15.3% (12.9 in the new and 17.2% in the group with
continuous asthma (p50.09)).
The prevalence of use of ICS varied from almost 50% in the
populations of asthmatics in the Netherlands, Belgium, UK
and Sweden to ,20% in the Italian and Swiss asthmatic
population samples (table 2). Less than half of those that had
used ICS in the previous 12 months were using them on a daily
basis during the last 3 months (table 2). Among the 121
C. JANSON ET AL. CHANGES IN USE OF ANTI-ASTHMATIC MEDICATION
c
EUROPEAN RESPIRATORY JOURNAL VOLUME 26 NUMBER 6 1049
subjects that were taking ICS daily in the ECRHS II, 38, 49 and
14% were using low, moderate and high doses, respectively.
Change in anti-asthmatic treatment in subjects with
continuous asthma
A total of 494 subjects in the random sample had symptomatic
asthma in ECRHS I. Of these, 424 (87.8%) still had symptomatic
asthma at the ECRHS II survey (fig. 2). In this group, there was
a significantly increased use of ICS and a decreased use of oral
b2-agonists and theophylline. Despite a significant increase in
daily use of ICS (fig. 3), only 17% of subjects with continuous
asthma used ICS on a daily basis (table 3). There was no
country heterogeneity in change in daily use of ICS or any
other type of therapy (p.0.1) except for a change in any use of
ICS within the last 12 months (test for heterogeneity p50.001),
chiefly explained by a very large increase observed in Belgium.
Excluding the Belgian centres, the increase in the use of ICS
was still highly significant (9.7 (4.0–15.3), without any country
heterogeneity (p.0.1)).
Change in asthma-related outcomes and health utilisation
Patients with continuous asthma reported significantly less
asthma attacks in the second survey compared with the first,
whereas no significant change was found in hospitalisations or
in the proportion that had seen a doctor within the previous 12
months (table 4). Only six out of the 209 patients that had not
seen a doctor had seen a nurse or a physiotherapist within the
previous 12 months. The decline in the proportion of patients
with more than four asthma attacks was larger in the group of
patients that had used ICS in both surveys compared with
patients that had not used ICS in any of the surveys (-38.6
(-58.2, -17.2)% versus -10.9 (-24.9, 4.7)%, p50.01). The sample
was too small to test the association between change in asthma
attacks and daily use of ICS or ICS use and hospitalisations.
Determinants for the start of use of ICS
When combining the random and symptomatic population
samples, 1,089 subjects fulfilled the criteria for symptomatic
asthma at the first survey and of those, 969 (89%) still had
symptomatic asthma. In this group, 150 had started using ICS
since the first survey. Males and smokers were less likely to
have started using ICS and this pattern was consistent across
countries (test for heterogeneity p.0.1; table 5). Restricting the
analysis to daily use of ICS gave similar results, with an
increased likeliness in females (OR (95% CI): 2.04 (1.07–3.89))
TABLE 2 Use of inhaled corticosteroids (ICS) in subjects with current symptomatic asthma in the random sample of the
European Community Respiratory Health Survey (ECRHS) II
Country Subjects n Use of ICS#," Use of ICS+,1
Not at all When needed Short course Continuously
Iceland 38 37 21 5 32 42
Norway 59 24 0 21 7 71
Sweden 124 47 29 7 14 50
Estonia 5 20 0 0 0 100
Germany 47 28 15 8 15 62
The Netherlands 15 40 0 0 33 67
Belgium 31 48 20 27 0 53
Switzerland 36 17 0 33 0 67
France 131 24 31 22 22 25
UK 79 47 24 14 8 54
Italy 36 19 29 0 43 29
Spain 81 27 14 23 27 36
USA 28 29 25 0 12 62
Australia 73 26 21 5 32 42
All subjects 783 32 23 15 15 48
All data presented as per cent unless otherwise specified. #: in previous 12 months; ": n5783; +: during last 3 months in subjects that have taken ICS during the previous
12 months; 1: n5252.
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FIGURE 2. Follow-up of asthmatics in the European Community Respiratory
Health Survey (ECRHS) I and change in asthma status between ECRHS I and II.
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and a decreased likeliness in smokers (OR (95% CI): 0.37 (0.16–
0.86)) to have started using ICS on a daily basis.
DISCUSSION
In a large, multicentre study, the proportion of participants
reporting the use of medications for asthma has increased over
an 8-yr period. At the same time there has been an increase in
symptomatic asthma in the study population. Despite a
widespread increase in the use of anti-asthma medication,
only one in six with diagnosed asthma and symptoms highly
suggestive of current active asthma, were taking inhaled
steroids daily. Differences in the use of inhaled corticosteroids
between males and females and smokers and nonsmokers that
were identified at baseline are still present in this cohort.
To the best of the current authors’ knowledge, ECRHS II is the
first population-based study of change in asthmatic pharma-
cotherapy in an international cohort. The time period studied
is of particular interest, since GINA guidelines were intro-
duced at the time of the first survey [3]. The main strength of
this investigation is that it is prospective and the methodology
of the study is the same in both surveys. However, a drawback
with this approach is that there were few indicators of asthma
severity in the first survey. Low-response rates in some centres
may be of concern, although in general, the direction of change
was consistent in centres and countries with low and high
response rates. Differences between responders and nonres-
ponders at baseline were relatively small, although there was
an under-representation of males and smokers among those
who participated in ECRHS II. This may have caused an
overestimation of the overall change in use of drugs but the
associations of sex and smoking with change are unlikely to be
altered.
The current authors’ definition of asthma was based on the
combination of a physician’s reported diagnosis and current
asthma-related symptoms. The same definition was used in the
previous study of ECRHS I [12] and has in previous studies’
populations been shown to have a relatively low sensitivity but
high specificity [18, 19]. An increase in the use of reported
asthma attacks and ‘‘any medicine for asthma’’ in this
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FIGURE 3. Net change in daily use of inhaled corticosteroids (ICS) in the
continuous asthmatics from the random sample of the European Community
Respiratory Health Survey (ECRHS) II, with the 95% confidence interval (CI) of the
centre. The area of each square is proportional to the reciprocal of the variance of
the estimate for the centre. ..........: combined random-effects estimate; e: has the
width of its 95% CI.
TABLE 3 Prevalence and change in different types of anti-asthmatic drugs in subjects with continuous symptomatic asthma from
the random sample
ECRHS I ECRHS II Net change?10 yr-1
Medication used in the last 12 months
Anti-asthmatics 63.8 66.9 3.4 (-1.8–8.5)
Inhaled anti-asthmatics 61.9 64.5 2.7 (-2.8–8.2)
Inhaled short-acting b2-agonists 55.8 57.2 0.9 (-4.7–6.6)
Inhaled long-acting b2-agonists 13.6
Inhaled anti-cholinergics 2.6 1.0 -1.5 (-3.5–0.5)
Inhaled corticosteroids 22.5 32.6 12.2 (6.6–17.8)
Inhaled cromones 6.1 2.4 -4.9 (-7.8– -2.1)
Oral anti-asthmatics 15.2 11.1 -4.1 (-8.7–0.5)
Oral b2-agonists 5.5 1.5 -4.2 (-6.7– -1.6)
Oral theophylline 8.2 2.6 -6.2 (-9.4– -3.0)
Oral anti-leukotrienes 1.2
Oral corticosteroids 6.9 7.4 1.1 (-2.4–4.7)
Medication used daily
Inhaled short-acting b2-agonists 9.0 6.8 -1.9 (-5.8–0.2)
Inhaled long-acting b2-agonists 8.3
Inhaled corticosteroids 10.3 17.2 8.1 (3.7–12.4)
Data presented as % or % (95% confidence interval). Total number of subjects was 423. ECRHS: European Respiratory Health Survey.
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population has been shown in a recent analysis of data from
both postal surveys (stage 1) in ECRHS I and II [20]. It is
difficult to know whether the increased prevalence of asthma
in the previous and present report is related to an actual
increase in asthma or a change in diagnostic threshold, with
more subjects with mild disease being diagnosed and treated
for asthma. In contrast to the present investigation, the postal
questionnaire did not include information on the use of
specific drugs, such as ICS or smoking history [20].
The current authors have observed a substantial increase in the
use of anti-asthmatics. The observed change in utilisation of
anti-asthmatics is probably a combined effect of an increased
prevalence of diagnosed asthma and a greater chance of
receiving inhaled corticosteroids once diagnosed. This result is
in accordance with both the recommendations from guidelines
[1–4] and reports of national trends in sales of anti-asthmatics
[5–7]. The current authors also found indications that asthma
control has improved, since people with asthma in both
surveys reported fewer asthma attacks at follow-up. This was
most noticeable in patients that used ICS in both surveys.
Because of the time period studied it is likely that these
improvements are related to guideline disseminations. It is also
possible that these improvements are in part related to
increased awareness of asthma in the current study’s cohort
as an effect of being a participant in a longitudinal study [21].
However, a study from New Zealand using ECRHS I data did
not find that repeated measurements introduced a bias in
prevalence rates of asthma and respiratory symptoms com-
pared with those obtained in a similar population studying
only one occasion [22].
However, the present study suggests that treatment reported
by many asthmatics is far from ideal. Amongst current
symptomatic asthmatics, only one in six reported taking them
on a daily basis. Other reports have shown that inhaled
corticosteroids are only used by a small proportion of
asthmatics in the general population [12, 23, 24], perhaps due
to relatively mild disease in some patients. Few of the subjects
from the current study were hospitalised for asthma but
asthma that prompts prescription of inhaled steroids is likely
to cause symptoms severe enough to influence an individual’s
health. Inhaled corticosteroids are of less therapeutic value if
not taken daily, and failure to do so will be less likely to
ameliorate symptoms. As found in ECRHS I [12], the majority
of patients had not seen a doctor or any other health
professional because of their asthma in the last 12 months.
Lack of regular medical review may be a reason for the failure
to report the use of ICS as recommended.
Although some countries are represented by only one centre,
there is evidence that there are marked national differences in
the use of ICS by physician-diagnosed asthmatics. Despite
general increases in the use of ICS and wide dissemination of
clear clinical guidelines for the treatment of asthma, the pattern
for higher usage of steroid inhalers in Northern Europe
compared with Southern Europe that was noted in the early
1990s is still apparent almost 10 yrs later [12]. There are several
possible explanations for these findings, such as different
therapy traditions or cultural differences at patient level, or at
the physician level. A geographical variation in asthma
severity is also another possible explanation.
The current study also shows that as physicians across Europe
are increasingly prescribing ICS they are decreasing the
prescribtion of other drugs, such as cromones, oral b2-agonists
and theophylline. The decreased use of the two latter drugs is
consistent with the recommendations of the GINA guidelines [3].
In the current investigation, it was observed that females with
asthma were more likely to have started using ICS when
compared with males. A higher use of ICS in females than in
males was also found in a recent study in the UK and the
Netherlands [7]. Like MARKS et al. [25], the current authors
TABLE 4 Prevalence and change in asthma-related
outcomes and doctor visits in subjects with
continuous symptomatic asthma from the
random sample
ECRHS I ECRHS II Net change?10 yr-1
Hospitalisations 2.2 1.4 -1.1 (-3.2–1.1)
More than one
asthma attack
43.4 33.9 -11.2 (-17.5– -4.9)
More than four
asthma attacks
28.7 16.0 -14.9 (-20.5– -9.1)
Seen by a doctor 40.6 35.6 -4.4 (-11.0–2.3)
Data presented as % or % (95% confidence interval). Total number of subjects
was 423. The recall period was 12 months for all variables. ECRHS: European
Respiratory Health Survey.
TABLE 5 Determinants for beginning using inhaled
corticosteroids (ICS) compared with non-ICS
users in the sample of subjects with continuous
asthma from the random and symptomatic
samples who had not used ICS in the previous
survey
Use of ICS OR (95% CI)
Age 10-yr increase 1.21 (0.85–1.74)
Female verus male 2.20 (1.36–3.55)
Never-smoker 1
Ex-smoker 0.96 (0.52–1.75)
Quitter 0.74 (0.35–1.59)
Smoker 0.44 (0.25–0.79)
Professionals and semiprofessionals 1
Non-manual 1.12 (0.60–2.08)
Manual 0.85 (0.46–1.57)
Low educational status# 1.04 (0.48–2.24)
No asthma attacks in the previous year 1
One to four asthma attacks 1.54 (0.91–2.61)
More than four asthma attacks 2.06 (1.15–3.68)
Early onset asthma f18 yrs old 1.06 (0.65–1.73)
Total subjects n5517. Adjusted for centre, sample, length of follow-up and the
variables in the table. #: entered separately in the table, replacing occupational
status.
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found that a lower proportion of asthmatic smokers were using
ICS compared with nonsmoking asthmatics. Lower usage of
anti-asthmatics in smokers was also found in a previous
investigation [26]. This may be explained by a reduced
therapeutic effect in smokers [27] or because smokers are less
perceptive and therefore less troubled by bronchoconstriction
[28]. Doctors may be more reluctant to introduce anti-
asthmatics for symptomatic smokers and instead concentrate
on smoking cessation. Some of the smokers may have chronic
obstructive pulmonary disease rather than asthma but as this
population was relatively young when diagnosed as having
asthma, the proportion of subjects misclassified in this way is
probably relatively low. No association was found between
socio-economic status and the use of ICS.
The current authors conclude that the prevalences of both
diagnosed symptomatic asthma and anti-asthmatic medication
have increased in this international cohort. The use of drugs for
the treatment of asthma and the level of asthma control, has
increased in a pattern consistent with current consensus
on treatment. However, despite increased use of inhaled
corticosteroids, a large majority of subjects with continuous
symptomatic asthma do not use this treatment on a daily
basis, particularly males and smokers with asthma. The
prognostic implication of these findings remains to be
investigated.
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